Technology

Baylin Technologies Confirms Payment of Debentures in Common Shares at Maturity and Exchange of Preferred Shares

Published

8 hours ago

June 24, 2026

TORONTO, June 24, 2026 /CNW/ – Baylin Technologies Inc. (the “Company”) (TSX: BYL) (OTCQB: BYLTF) confirms that it has exercised its right to repay the principal amount of its 8.5% Convertible Unsecured Debentures (the “Debentures”) due June 30, 2026 (the “Maturity Date”), through the issuance of common shares of the Company (the “Common Shares”), subject to compliance with the terms of the Debentures (the “Common Share Repayment Right”).

Pursuant to the exercise of the Common Share Repayment Right, upon surrender of the Debentures, the Company will issue a total of 18,202,846 Common Shares in satisfaction of the principal amount of Debentures outstanding on the Maturity Date. The number of Common Shares to be issued is equal to the principal amount of the Debentures outstanding (currently, $5,115,000) divided by 95% of the current market price of $0.296 per Common Share (calculated based on the volume weighted average trading price of the Common Shares on the Toronto Stock Exchange (the “TSX”) for the 20 consecutive trading days ending five trading days before the Maturity Date, in accordance with the terms of the Debentures). The issuance of Common Shares in connection with the exercise of the Common Share Repayment Right is subject to customary conditions, including approval of the TSX.

The Company has also agreed to exchange all of its $3,950,000 outstanding 10% Cumulative Redeemable Retractable Series A and Series B Preferred Shares (the “Exchanged Preferred Shares”) held by the Company’s controlling shareholder, 2385796 Ontario Inc. (the “controlling shareholder”), together with accrued and unpaid dividends thereon, for a total of 16,171,876 Common Shares, issued on a private placement basis at $0.281 per Common Share (the “Exchanged Common Shares”), plus a cash payment of approximately $0.25 in lieu of fractional shares (the “Exchange”). Mr. Jeffrey C. Royer, Chairman of the Board of Directors of the Company, exercises control and direction over securities held by the controlling shareholder. Mr. Royer currently exercises control and direction over approximately 50.3% of the issued and outstanding Common Shares. After giving effect to the Exchange, Mr. Royer is expected to exercise control and direction over approximately 53.4% of the issued and outstanding Common Shares.

The Exchange constitutes a “related-party transaction”, as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”), but is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the subject matter of the Exchange (being the Exchanged Preferred Shares acquired by the controlling shareholder), nor the consideration paid for the Exchange (being the Exchanged Common Shares plus a cash payment in lieu of fractional shares), exceed 25% of the Company’s market capitalization.

The Exchange has been approved by the Board of Directors of the Company, with Mr. Jeffrey C. Royer having recused himself. Completion of the Exchange is subject to customary conditions for a transaction of this type, including approval of the TSX. Subject to satisfaction of the conditions, the Exchange is expected to be completed on or about June 26, 2026.

ABOUT BAYLIN

Baylin is a leading diversified global wireless technology company focused on the research, design, development, manufacturing and sales of passive and active radio frequency and satellite communications products, and the provision of supporting services. For more information, visit www.baylintech.com.

FORWARD-LOOKING STATEMENTS

This release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are not statements of historical fact. Rather, they are disclosure regarding conditions, developments, events or financial performance that we expect or anticipate may or will occur in the future, including, among other things, information or statements concerning our objectives and strategies to achieve those objectives, statements with respect to management’s beliefs, estimates, intentions and plans, and statements concerning anticipated future circumstances, events, expectations, operations, performance or results. Forward-looking statements can be identified generally by the use of forward looking terminology, such as “anticipate”, “believe”, “could”, “should”, “would”, “estimate”, “expect”, “forecast”, “indicate”, “intend”, “likely”, “may”, “outlook”, “plan”, “potential”, “project”, “seek”, “target”, “trend” or “will” or the negative or other variations of these words or other comparable words or phrases, which is intended to identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements in this release include statements regarding the number of Common Shares to be issued in repayment of the Debentures pursuant to the Common Share Repayment Right and in connection with the Exchange and the controlling shareholder’s percentage ownership of the outstanding Common Shares. Forward-looking statements are based on assumptions that the Company believes are reasonable, including assumptions regarding the principal amount of Debentures outstanding on the Maturity Date and the Company’s ability to complete the repayment of the Debentures and the Exchange, in each case, on the terms and timelines anticipated and by satisfying the required conditions to completion.

Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results to differ materially from those expressed or implied in such statements. These risks include risks related to the failure to complete the repayment of the Debentures and the Exchange and other risks detailed in the Company’s continuous disclosure filings available on SEDAR+ at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this release. Unless required by applicable law, the Company does not intend, and does not assume any obligation, to update any forward-looking statements.

SOURCE Baylin Technologies Inc.

Technology

AI in Healthcare Market to Reach USD 505.6 Billion by 2033, Driven by Rapid Adoption of AI-Powered Clinical Solutions and Digital Healthcare Transformation

Published

39 minutes ago

June 24, 2026

Global AI in Healthcare Market Expected to Expand at 38.90% CAGR from 2026 to 2033 as Healthcare Systems Embrace Predictive Analytics, Precision Medicine, and Automation

SAN FRANCISCO, June 24, 2026 /PRNewswire/ — The global artificial intelligence (AI) in healthcare market is projected to witness significant growth, reaching USD 505.59 billion by 2033, according to a new report by Grand View Research, Inc. The market was estimated at USD 36.7 billion in 2025 and is anticipated to grow from USD 50.7 billion in 2026 to USD 505.6 billion by 2033, expanding at a compound annual growth rate (CAGR) of 38.90% during the forecast period from 2026 to 2033.

The increasing demand for advanced healthcare technologies, rising adoption of artificial intelligence-driven clinical decision support systems, growing healthcare data volumes, and the need for improved patient outcomes are accelerating the integration of AI across healthcare ecosystems. AI technologies are enabling healthcare providers to transition from traditional reactive models toward predictive, personalized, and preventive healthcare approaches.

AI Transforming Healthcare Delivery Through Advanced Analytics and Automation

Artificial intelligence is emerging as a transformative technology within the healthcare industry by enabling faster diagnosis, improved treatment planning, operational efficiency, and enhanced patient engagement. AI-powered solutions are being increasingly deployed across medical imaging, clinical decision support, drug discovery, patient monitoring, administrative automation, and personalized medicine applications.

Healthcare organizations are leveraging machine learning, natural language processing, computer vision, and deep learning technologies to analyze complex medical datasets, identify disease patterns, and support healthcare professionals with actionable insights. The ability of AI systems to process large-scale clinical information is helping improve diagnostic accuracy and optimize healthcare workflows.

Clinical decision support systems powered by AI are becoming increasingly important as healthcare providers seek real-time insights to enhance decision-making and improve patient care outcomes. These solutions assist physicians by analyzing patient information, identifying potential risks, and supporting evidence-based treatment strategies.

Get Free Sample of this Research Report for more latest industry insights

Rising Healthcare Data Volumes and Digital Transformation Fuel Market Growth

The rapid digitization of healthcare infrastructure is one of the major factors contributing to the expansion of the AI in healthcare market. The increasing adoption of electronic health records (EHRs), connected medical devices, wearable technologies, and remote patient monitoring solutions is generating substantial amounts of healthcare data.

AI platforms are helping organizations convert this data into meaningful clinical and operational intelligence. Healthcare providers are increasingly adopting AI solutions to improve resource utilization, streamline workflows, reduce operational costs, and deliver more personalized patient experiences.

The growing prevalence of chronic diseases, increasing healthcare expenditure, and rising demand for efficient healthcare delivery models are further supporting market growth. AI-driven solutions are enabling healthcare systems to improve early disease detection, enhance treatment outcomes, and support continuous patient monitoring.

Software Segment and AI-Based Solutions Drive Healthcare Innovation

The AI in healthcare market is segmented by component, application, technology, end use, and region. The market includes hardware, software, and services components, with AI software solutions playing a critical role in enabling advanced analytics, automation, and decision-support capabilities.

AI applications across clinical trials, cybersecurity, medical imaging analysis, robotic-assisted procedures, drug discovery, and healthcare management are expanding rapidly as organizations invest in intelligent healthcare infrastructure.

The integration of AI into clinical research is also creating new opportunities by improving patient recruitment, accelerating data analysis, and supporting faster development of medical innovations. AI technologies are helping pharmaceutical and biotechnology companies analyze complex biological data and enhance research efficiency.

Growing Adoption of AI in Precision Medicine and Personalized Healthcare

The increasing focus on personalized medicine is creating new growth opportunities for AI adoption in healthcare. AI algorithms can analyze patient-specific information, including medical history, genetic data, and clinical indicators, to support individualized treatment strategies.

Precision healthcare initiatives are increasingly using AI to identify disease risks, predict treatment responses, and improve therapeutic outcomes. The technology is supporting advancements in areas such as oncology, cardiology, neurology, and diagnostics by enabling more accurate and timely medical interventions.

AI-powered healthcare platforms are also contributing to remote care models by supporting virtual healthcare services, remote monitoring, and patient engagement solutions. These capabilities are becoming increasingly important as healthcare systems worldwide focus on improving accessibility and efficiency.

North America Leads AI Healthcare Adoption While Asia Pacific Presents Growth Opportunities

North America continues to represent a significant region for AI healthcare adoption due to advanced healthcare infrastructure, strong technology investments, and increasing implementation of digital health solutions. The region benefits from the presence of leading technology companies, healthcare organizations, and research institutions focused on AI innovation.

Meanwhile, Asia Pacific is expected to witness strong growth opportunities due to increasing healthcare digitalization, rising investments in healthcare technology, improving healthcare infrastructure, and growing demand for advanced medical solutions.

Countries across emerging markets are increasingly exploring AI applications to improve healthcare accessibility, address workforce challenges, and enhance diagnostic capabilities.

Browse more Research Reports in Healthcare IT Industry

Competitive Landscape and Industry Outlook

The global AI in healthcare market includes several prominent technology and healthcare companies focusing on innovation, strategic partnerships, and development of advanced AI platforms. Key companies profiled in the market include Microsoft, IBM, NVIDIA Corporation, Intel Corporation, GE Healthcare, Google, Medtronic, Oracle, Medidata, Merck, and IQVIA.

Market participants are investing in research and development activities, AI-enabled healthcare platforms, cloud-based solutions, and strategic collaborations to strengthen their market position.

As healthcare organizations continue adopting artificial intelligence technologies, AI is expected to play a central role in improving clinical decision-making, operational efficiency, and patient outcomes globally.

Grand View Research Report Coverage

The Grand View Research report provides an in-depth analysis of the artificial intelligence in healthcare market, including market size, growth trends, competitive landscape, segment analysis, and regional insights. The report covers historical data from 2021 to 2025 and provides forecasts for the period from 2026 to 2033.

To learn more about growth opportunities in the AI In Healthcare Market, access the full report from Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Browse GVR’s U.S. Healthcare Facility Mapping & Intelligence Platform

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Blog – https://globalindustryherald.com/

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-healthcare-market-to-reach-usd-505-6-billion-by-2033–driven-by-rapid-adoption-of-ai-powered-clinical-solutions-and-digital-healthcare-transformation-302808113.html

Technology

Club Offers for Travel Enthusiasts in the U.S.

Published

39 minutes ago

June 24, 2026

NEW YORK, June 24, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces a new Club Offer for Club Members in the U.S.

Rigorously vetted and negotiated for us travel enthusiasts:

$899—NEW MEXICO ALL-INCLUSIVE VACATION WITH FLIGHTS
This Riviera Maya resort has been completely transformed. In September, it will debut as a luxurious Kimpton resort. Everything has been refreshed, from the suites to the restaurants and public spaces. This package includes roundtrip flights, 5 nights’ accommodations, airport transfers and all meals and drinks. You can also add additional nights for longer stays. It’s rare to find opening-season rates this low at a brand-new luxury resort, especially when rooms here sell for $400-$600 per night. We’ve negotiated this Club Offer just for us.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Media Contact:

Jonathan Jones – New York
jjones@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-the-us-302809648.html

SOURCE Travelzoo

Technology

Royce Micro-Cap Trust (NYSE: RMT) as of May 31, 2026

Published

39 minutes ago

June 24, 2026

NEW YORK, June 24, 2026 /PRNewswire/ —

Average weekly trading volume of approximately 531,385 sharesFund’s adviser has more than 50 years of small- and micro-cap investment experience

CLOSING PRICES AS OF 05/31/26

NAV

15.73

MKT

14.04

AVERAGE ANNUAL TOTAL RETURN AS OF 05/31/26

NAV (%)

MKT (%)

One-Month*

6.21

6.20

Year to Date*

35.72

36.93

One-Year

70.80

73.35

Three-Year

28.50

29.82

Five-Year

11.90

11.99

10-Year

15.25

15.81

*Not Annualized

Important Performance and Expense Information

All performance information reflects past performance, is presented on a total return basis, net of the Fund’s investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted. Returns as of the recent month-end may be obtained at www.royceinvest.com. The market price of the Fund’s shares will fluctuate, so that shares may be worth more or less than their original cost when sold.

The Fund normally invests in micro-cap companies, which may involve considerably more risk than investing in larger-cap companies. The Fund’s broadly diversified portfolio does not ensure a profit or guarantee against loss.

PORTFOLIO DIAGNOSTICS

Average Market Cap1

$1070.9M

Weighted Average P/B2

2.3x

Net Assets

$847.4M

Net Leverage

1.5 %

1Geometric Average: This weighted calculation uses each portfolio holding’s market cap in a way designed to not skew the effect of very large or small holdings; instead, it aims to better identify the portfolio’s center, which Royce believes offers a more accurate measure of average market cap than a simple mean or median.

2Harmonic Average: This weighted calculation evaluates a portfolio as if it were a single stock and measures it overall. It compares the total market value of the portfolio to the portfolio’s share in the earnings of its underlying stocks.

The Price-to-Book, or P/B, Ratio is calculated by dividing a company’s share price by its book value per share.

Net leverage is the percentage, in excess of 100 %, of the total value of equity type investments, divided by net assets.

Portfolio Composition

TOP 10 POSITIONS

% OF NET ASSETS (SUBJECT TO CHANGE)

5N Plus

1.8

Cohu

1.5

Ichor Holdings

1.5

NWPX Infrastructure

1.4

Ultra Clean Holdings

1.4

ADTRAN Holdings

1.4

EZCORP Cl. A

1.3

Vishay Precision Group

1.3

Bel Fuse Cl. B

1.3

Graham Corporation

1.3

TOP FIVE SECTORS

% OF NET ASSETS (SUBJECT TO CHANGE)

Industrials

28.4

Information Technology

25.0

Financials

12.8

Health Care

11.9

Consumer Discretionary

10.8

Recent Developments
Royce Micro-Cap Trust, Inc. is a closed-end diversified investment company whose shares of Common Stock (RMT) are listed and traded on the New York Stock Exchange. The Fund’s investment goal is long-term capital growth, which it seeks by investing primarily in equity securities of companies that, at the time of investment, have market capitalization of $1 billion or less.

Daily net asset values (NAVs) for Royce Micro-Cap Trust, Inc. are now available on our website and online through most ticker symbol lookup services and on broker terminals under the symbol XOTCX. For more information, please call The Royce Funds at (800) 221-4268 or visit our website at www.royceinvest.com

An investor in Royce Micro-Cap Trust should consider the Fund’s investment goals, risks, fees, and expenses carefully before investing.

Important Disclosure Information
Closed-End Funds are registered investment companies whose shares of common stock may trade at a discount to their net asset value. Shares of each Fund’s common stock are also subject to the market risks of investing in the underlying portfolio securities held by the Fund. Royce Fund Services, LLC. (“RFS”) is a member of FINRA and has filed this material with FINRA on behalf of each Fund. RFS does not serve as a distributor or as an underwriter to the closed-end funds.

View original content:https://www.prnewswire.com/news-releases/royce-micro-cap-trust-nyse-rmt-as-of-may-31-2026-302809653.html

SOURCE Royce Micro-Cap Trust, Inc.